購読する
モデル製品
カスタムサービス
創薬研究
コミュ二ティー
hCRBN/Rag2-KO(BALB/c) Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
hCRBN/Rag2-KO(BALB/c) Mouse
製品名
hCRBN/Rag2-KO(BALB/c) Mouse
製品ID
C002136
系統名
BALB/cAnCya-Crbnem1(hCRBN)Rag2em1/Cya
背景情報
BALB/cAnCya
状況
このマウス系統を論文で使用する場合は、「hCRBN/Rag2-KO(BALB/c) Mouse(カタログ番号C002136)はサイアジェンから購入しました。」と引用してください。
Tumor Target Humanized Mouse ModelsImmune Target Humanized Mouse ModelsOther Immunodeficient Mice
ADC
AOC
Gene Editing Therapy
PROTAC & Molecular Glue
CDS Humanized Models
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
Tumor Target Humanized Mouse ModelsImmune Target Humanized Mouse ModelsOther Immunodeficient Mice
ADC
AOC
Gene Editing Therapy
PROTAC & Molecular Glue
CDS Humanized Models
基本情報
関連リソース
基本情報
遺伝子別名
Rag-2, MRT2, MRT2A
染色体
Chr 2, Chr 3
MGI ID
さらに
系統詳細
The CRBN gene is located on human chromosome 3 and is broadly expressed across multiple tissues, with particularly prominent expression in brain tissue, kidney parenchyma, skeletal muscle, and various immune cell populations, including monocytes, macrophages, dendritic cells, and B lymphocytes [1]. The Cereblon protein encoded by this gene serves as a critical substrate recognition receptor of the CRL4-CRBN E3 ubiquitin ligase complex, playing an important regulatory role within cells. This complex specifically recognizes target proteins and mediates their ubiquitination, subsequently directing these proteins into the proteasomal degradation pathway, thereby precisely regulating multiple fundamental cellular processes, including protein homeostasis, ion channel transport activity, and AMPK signaling pathway transduction [1-2]. In the field of genetic disease research, it is well established that loss-of-function mutations in the CRBN gene are closely associated with the pathogenesis of non-syndromic intellectual disability with an autosomal recessive inheritance pattern [2]. Furthermore, as the primary molecular target of targeted protein degradation (TPD) therapy, the Cereblon protein can induce selective degradation of specific transcription factors by modulating the enzymatic activity of the CRL4-CRBN complex and altering its substrate recognition properties. This molecular mechanism has become an important theoretical foundation for the clinical treatment of malignant hematological diseases such as multiple myeloma, giving rise to various drug types, including molecular glues and proteolysis-targeting chimeras (PROTACs) [3-5].
The protein encoded by the RAG2 gene, together with the RAG1 protein, constitutes the RAG complex, which plays an essential role in V(D)J recombination during the maturation of B cells and T cells. During V(D)J recombination, the RAG complex attaches to recombination signal sequences (RSS) on the DNA, which are located adjacent to V, D, or J segments. The RAG complex cleaves the DNA between the signal sequences and the segments, enabling the segments to separate and move to different regions of the gene. This process is repeated multiple times in B cells and T cells, allowing V, D, and J segments to be arranged in different combinations. The resulting protein diversity provides a broader capability for recognizing foreign invaders and allows the body to effectively defend against infections. RAG2 not only participates in the catalysis of the reaction but also regulates the reaction by controlling access to specific genomic loci [6].
The hCRBN/Rag2-KO(BALB/c) mouse is a combined genetically modified model obtained by crossing hCRBN(BALB/c) mice (Catalog No.: C001724) with Rag2-KO(BALB/c) mice. The hCRBN/Rag2-KO(BALB/c) mouse can be used for screening, pharmacodynamic evaluation, safety evaluation, and mechanism of action studies of drugs targeting CRBN. Based on the Rag2 knockout background, this model is an immunodeficient mouse model with T and B cell deficiency, which can be used for broad research in various oncology and immunology fields, providing a preclinical research tool for exploring the role of CRBN-targeted intervention in the context of related diseases.
参考文献
Barankiewicz J, Salomon-Perzyński A, Misiewicz-Krzemińska I, Lech-Marańda E. CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma. Cancers (Basel). 2022 Sep 16;14(18):4492.
Zhou L, Xu G. The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases. J Mol Biol. 2022 Mar 15;434(5):167457.
An J, Zhang X. Crbn-based molecular Glues: Breakthroughs and perspectives. Bioorg Med Chem. 2024 Apr 15;104:117683.
Yamamoto J, Ito T, Yamaguchi Y, Handa H. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders. Chem Soc Rev. 2022 Aug 1;51(15):6234-6250.
Thapa R, Bhat AA, Gupta G, Renuka Jyothi S, Kaur I, Kumar S, Sharma N, Prasad GVS, Pramanik A, Ali H. CRBN-PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications. Chem Biol Drug Des. 2024 Nov;104(5):e70009.
Schatz DG. V(D)J recombination. Immunol Rev. 2004 Aug;200:5-11.
系統作製戦略
The hCRBN/Rag2-KO(BALB/c) mouse is a genetically modified model generated by crossing hCRBN(BALB/c) mice (Catalog No.: C001724) with Rag2-KO(BALB/c) mice.

Figure 1. Gene editing strategy of hCRBN(BALB/c) mice. The exon 2 to partial intron 2 of mouse Crbn was replaced with Exon 2~11 of Human CRBN CDS-BGH pA cassette.

Figure 2. Gene editing strategy of Rag2-KO(BALB/c) mice. The mouse Rag2 gene is located on chromosome 2 and contains three exons. Both the start and stop codons are located on exon 3. The Rag2 gene knockout was achieved by targeting exon 3 using gene editing technology.
適用分野
Screening, pharmacodynamic evaluation, safety evaluation, and mechanism-of-action studies of drugs targeting the CRBN protein;
Screening, development, and preclinical efficacy evaluation of CRBN-based targeted protein degradation (TPD) therapies;
Research on the pathological mechanisms and therapeutic approaches for non-syndromic intellectual disability;
Research on the pathological mechanisms and therapeutic approaches for malignant hematological diseases such as multiple myeloma.
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
